Share on LinkedInShare on LinkedIn

ARTICLE · 25 FEBRUARY 2015

First Round Of BPCIA Litigation: Declaratory Judgment Act Can’t Be Used To Avoid The "Patent Dance"

Five years after the passage of the BPCIA, litigation concerning the statute's patent procedures has recently begun to reach the courts.

United StatesIntellectual Property

As the 1984 Hatch-Waxman Act did for generic small-molecule drugs, the Biologics Price Competition and Innovation Act of 2009 created a new regulatory pathway for the approval of biosimilar or interchangeable versions of biological medicines.  The BPCIA also created a new legal framework for resolving associated patent disputes, sometimes called the "patent dance" because of its intricate sequence of exchanges.  Five years after the passage of the BPCIA, litigation concerning the statute's patent procedures has recently begun to reach the courts.  To date, there have been four reported decisions (arising from three cases) addressing patent disputes between biosimilar makers and patent holders: a Northern District of California decision (Sandoz Inc. v. Amgen Inc., 2013 U.S. Dist. LEXIS 161233 (N.D. Ca. Nov. 12, 2013) that was affirmed by the Federal Circuit (773 F.3d 1274 (2014)) and two cases from the Southern District of New York (Celltrion Healthcare Co., Ltd. v.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from